MR-guided brachytherapy for ablation of small liver tumors to optimize dose application

MR-guided brachytherapy for ablation of small liver tumors to optimize dose application - MR. BRIGHT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031058

Enrollment

Registered

2023-09-20

Start date

2023-12-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: The intervention is performed during hospitalization. After the intervention, patients are followed up by the outpatient clinic of the Department of Radiology and receive an MRI of the liver

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Clinical indication for local ablative therapy of liver tumors (liver metastases or primary liver tumors). The indication for intervention in this case must be independent of the presented study. Maximum lesion size 3 cm

Exclusion criteria

Exclusion criteria: Contraindication to MRI examination

Design outcomes

Primary

Measure	Time frame
Primary endpoint is the detection of non-target radiation exposure of the liver (ratio: non-target volume exposed with target dose to volume of clinical target volume) with propensity score match analysis (criteria: Size of target lesion, tumor entity (or target dose)) to non-target radiation exposure under computed tomographic guidance.	—

Secondary

Measure	Time frame
- Local control rate (12 months), - local control rate according to variable "focal thermal ablation accessible yes/no" (12 months)	—

Countries

Germany

Contacts

Public ContactMax Seidensticker

LMU München

max.seidensticker@med.uni-muenchen.de+4989440076642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026